from very call. business results our some QX and Bio and to and expect Thank Thank our the you you, everyone. discuss recent good acquisitions Rod, Astero for pleased and performing of we how SAVSU. joining details what provide the is and I'm afternoon,
up XX% last $X.X was year. over QX total QX revenue million
customers regenerative sales and our distributors and driven period Second compared a XX% XX% primarily same our to quarter revenue from by to increase the medicine direct growth was XXXX. growth in
of product Astero and segment. we included high-growth We Therapeutics, million, on with In Bio, and the biopreservation thaw April Casebia, BriaCell, revenue and of from $X.X Rubius our gene generated from new XX media coming in customers the $XXX,XXX automated media gained total Cogen JangoBio, XX Neon therapy new biopreservation Notable acquisition gene that X. closed therapy Lacerda, Therapeutics cell BlueRock Calixir, cell Bio, GenCure, Therapeutics. customers Layal, Calidi sales
clinical cross-reference FDA cell XX supporting Also new in file use master we and gene QX trials. processed therapy letters in additional our products of
for We the support concentration product also increased China. a regulatory saw request scientific and from U.S. outside in customers with
in thaw customers biopreservation our and were nearly sales first full the importantly product very existing activity. that Fisher XX automated through XX% came and several pleased off new orders these to gained quarter automated also to Scientific, It's media e-commerce was of thaw direct-selling is augmenting customers. a QX strong noteworthy which product report these We our that of of start. of I'm platform we're QX
by driven our sales that to as the for opportunity The capture own cross-selling driver thaw were acquisition. stated Astero automated marketing new a orders the and remaining product activities we
Pat Bio, thaw and automated Pharma, bluebird Adicet BlueRock new notable included Editas Therapeutics, Biologics, Beam Therapeutics, customers TxCell. bio, So, product Bio Medicine, SQZ Patheon
on million will optimistic automated full Prelaunched designed achieve opportunity, that thaw for the million demand was CB is year guidance we the we of frozen product cryobag version. thaw new Continuing track packaged $X We're revenue biologics good $X of launch building. product CB our making and thaw in provided actively cryobags. XXXX. ThawSTAR to we're are automated our with very QX for progress consistently and ThawSTAR
supplier further solutions and of strengthens closing our the this manufacture, a leading therapeutics. SAVSU. We announced gene to position believe disruptive, of acquisition of used stores distribution just and enabling cell of now the in as Turning our
this customers' for and SAVSU we establishing runs therapy tools and and portfolio therapy and provide highly will manufacturing in level SAVSU's as opportunities the our ecosystem. best-in-class cell in critical bioproduction us is evo gene footprint cell varied a to our a workflow. tools distribution system believe position and increase engagement gene provider our
serving We tech-support and levers and that marketing the highly advanced coupled therapy infrastructure space. gene competitive specialty offers the container of sales, technologies, valuable have a the go-to-market world-wide and partnerships most that strategy the leading SaaS with couriers, cell
whom XX January has and look this decisions in evo full in system initial of several therapy to by gene all validation the forward various marquee year, of cell are stages been used of developers and We months. announcing Since product coming companies, by the shipments product gene and therapies in adoption evo cell adoption.
key other that product therapies. in-transit providing to enhanced differentiator is and CAR the A SAVSU these and highly cell therapy and high-value companies of life-saving, potentially platform approach integrated T-cell gene value, of protection
damage significant in-transit both Both can for the temperature in shock payload increased loss shippers for of catastrophe developer. economic events patient from risk excursions. the mechanical therapy these and the potential Traditional and result of biologic a
rate have shipments, and Several many companies product driving risk payload loss of of reduce SAVSU validations. are in-transit can the an innovations is system that useable experienced of engaged the accelerated with evo
revenue on in additional bullish. Rod expectations comments few for will a minutes. Our is evo outlook our provide
about the and cold and very regenerative again, through the Astero common to our thaw media, that SAVSU. important dynamic clinical acquisition drive manufacturing. evo derisking continue chain demand we will automated system. and commericial therapy running gene It's management products all reiterate medicine space There and in theme will is for trials believe I a cell biopreservation of
a current derisk of a paradigm believe broader for on We the is positive pay-on-cure potential and payment the predicated dynamic a each therapy. into portfolio, patient. environment of patient since response product nonviable perspective will to dose tools our evolving our support can with the this growing delivering customers reimbursement to The adoption
failure. and Simply therapeutic economic put, a dose non-viable to can delivering lead
bioproduction of derisk delivery gene best-in-class portfolio growing and therapies. tools cell manufacturing development, and can Our of
most and contributors. revenue was XX% indirect key our volume of significantly our QX growth to up distributors was from QX year. by increased now over revenue from driven last distributors. The worldwide order Turning network
continue We distribution provided gene end-users we our expanded cell therapy USA. regulatory, into QX, to partners an outside space. to the and filing the several reach technical And support by in see
back turn over Rod the for our I'll Now to present call to financial highlights QX.
